Candel Therapeutics Reports Q3 2026 Results, $203.1 Million in Cash

Candel Therapeutics reported a third-quarter 2026 net loss of $21.9 million, compared with a loss of $11.3 million a year earlier. Cash and cash equivalents were $203.1 million at September 30, which the company expects to fund its current operating plan into the second quarter of 2028. The company…